Case Report
Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case
Javier Munoz* and Philip KuriakoseDepartment of Hematology and Oncology, Henry Ford Hospital, 2799 W, Grand Blvd, Detroit Michigan 48202, USA
- Corresponding Author:
- Javier Munoz
Department of Hematology and Oncology
Henry Ford Hospital, Hematology-Oncology
2799 West Grand Blvd, Detroit, MI 48202, USA
Tel: 713-792-3934 / 713-854-6211
Fax: 713-792-3983
E-mail: Javier.munoz@me.com
Received Date: May 02, 2012; Accepted Date: June 14, 2012; Published Date: June 18, 2012
Citation:Munoz J, Kuriakose P (2012) Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case. J Palliative Care Med 2:118. doi:10.4172/2165-7386.1000118
Copyright: © 2012 Munoz J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
A 54-year-old male presented with shortness of breath and was diagnosed with pulmonary emboli. Laboratory studies revealed hemolytic anemia. Flow cytometry showed a prominent white blood cell clone without CD59 in 85% (NV 0-3.0) and red blood cells with 8.5% CD59 absence (NV 0-3.0) confirming a diagnosis of paroxysmal nocturnal hemoglobinuria. Eculizumab was started to decrease the possibility of a thrombotic recurrence, with incidentally, a marked subjective improvement of symptomatology, as fatigue, was seen. We reviewed current literature regarding the improvement in fatigue seen in patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
